Prolactin Does Not Require Insulin-Like Growth Factor Intermediates but Synergizes with Insulin-Like Growth Factor I in Human Breast Cancer Cells
Open Access
- 1 April 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 6 (4), 634-643
- https://doi.org/10.1158/1541-7786.mcr-07-2069
Abstract
Insulin-like growth factor (IGF)-II is a required intermediate for prolactin-induced up-regulation of cyclin D1 and proliferation in normal murine mammary epithelial cells in vivo and in vitro. However, we have recently shown that prolactin can rapidly induce cyclin D1 protein expression and subsequent proliferation in the MCF-7 human breast cancer cell line, suggesting that prolactin actions can be independent of IGFs in breast disease. Here, we investigate the relationship between these factors and show that prolactin up-regulated transcript levels of both IGF-I and IGF-II, but only after increases in cyclin D1 protein were observed. Moreover, prolactin increased cyclin D1 in the presence of the IGF-I receptor neutralizing antibody αIR3. However, on cotreatment, IGF-I and prolactin elicited cooperative phosphorylation of extracellular signal–regulated kinases 1 and 2 and protein kinase B/AKT, but not signal transducer and activator of transcription 5. This interaction extended to increased activation of activating protein-1 enhancer elements, phosphorylation of glycogen synthase kinase 3β, induction of cyclin D1, and ultimately, increased cell number. It also increased invasive behavior, which correlated with elevated matrix metalloproteinase-2 transcript levels. Interestingly, prolactin augmented phosphorylation at Tyr1135 and Tyr1136 of IGF-I receptor on cotreatment with IGF-I, although prolactin alone had no effect. Together, these data indicate that strong cooperative cross talk between prolactin and IGF-I augments biological processes associated with neoplastic progression, with implications for therapeutic strategies. (Mol Cancer Res 2008;6(4):634–43)Keywords
This publication has 51 references indexed in Scilit:
- Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell contextOncogene, 2007
- Disrupting insulin-like growth factor signaling as a potential cancer therapyMolecular Cancer Therapeutics, 2007
- Prolactin and breast cancer riskCancer Letters, 2006
- Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cellsOncogene, 2006
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic miceOncogene, 2003
- Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signalingOncogene, 2003
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- The contradictions of the insulin-like growth factor 1 receptorOncogene, 2000
- Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cellsEuropean Journal of Cancer, 1993